Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024
Krystal Biotech (NASDAQ: KRYS) has scheduled its third quarter 2024 financial results announcement for Monday, November 4, 2024, before U.S. markets open. The company's management will host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a business update. A live webcast will be available, and a replay will be accessible for 30 days on the company's investor website.
Krystal Biotech (NASDAQ: KRYS) ha programmato l'annuncio dei suoi risultati finanziari del terzo trimestre 2024 per lunedì 4 novembre 2024, prima dell'apertura dei mercati statunitensi. La direzione dell'azienda ospiterà una conference call e un webcast alle 8:30 ET dello stesso giorno per discutere i risultati e fornire aggiornamenti sull'attività. Sarà disponibile un webcast dal vivo, e una registrazione sarà accessibile per 30 giorni sul sito web per investitori dell'azienda.
Krystal Biotech (NASDAQ: KRYS) ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el lunes 4 de noviembre de 2024, antes de la apertura de los mercados estadounidenses. La dirección de la compañía llevará a cabo una llamada de conferencia y un webcast a las 8:30 am ET el mismo día para discutir los resultados y ofrecer una actualización del negocio. Se dispondrá de un webcast en vivo y una repetición estará accesible durante 30 días en el sitio web de inversores de la empresa.
크리스탈 바이오텍 (NASDAQ: KRYS)는 2024년 11월 4일 월요일 미국 시장 개장 전 2024년 3분기 재무 결과 발표를 예정하고 있습니다. 회사 경영진은 같은 날 오전 8:30 ET에 결과를 논의하고 사업 업데이트를 제공하기 위해 컨퍼런스 콜 및 웹캐스트를 개최할 것입니다. 실시간 웹캐스트가 제공되며, 회사의 투자자 웹사이트에서 30일 동안 재생할 수 있습니다.
Krystal Biotech (NASDAQ: KRYS) a programmé l'annonce de ses résultats financiers du troisième trimestre 2024 pour le lundi 4 novembre 2024, avant l'ouverture des marchés américains. La direction de l'entreprise organisera un appel conférence et un webcast à 8h30 ET ce même jour pour discuter des résultats et fournir une mise à jour de l'activité. Un webcast en direct sera disponible, et une rediffusion sera accessible pendant 30 jours sur le site Web des investisseurs de l'entreprise.
Krystal Biotech (NASDAQ: KRYS) hat die Bekanntgabe seiner Finanzergebnisse für das dritte Quartal 2024 für Montag, den 4. November 2024, vor der Eröffnung der US-Märkte angesetzt. Das Management des Unternehmens wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und ein Webcast veranstalten, um die Ergebnisse zu erörtern und ein Unternehmensupdate zu geben. Ein Live-Webcast wird verfügbar sein, und eine Aufzeichnung wird für 30 Tage auf der Investorenseite des Unternehmens zugänglich sein.
- None.
- None.
PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its third quarter 2024 financial results on Monday, November 4, 2024, prior to the open of U.S. markets.
The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, November 4, 2024, to discuss the financial results and provide a business update.
Investors and the general public can access the live webcast at: https://www.webcaster4.com/Webcast/Page/3018/51458.
For those unable to listen to the live webcast, a replay will be available for 30 days on the Investors section of the Company’s website at www.krystalbio.com.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
FAQ
When will Krystal Biotech (KRYS) release Q3 2024 earnings?
What time is Krystal Biotech's (KRYS) Q3 2024 earnings call?
How can I access Krystal Biotech's (KRYS) Q3 2024 earnings webcast?
